SCHEMBL4236608

SCHEMBL4236608

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4ccc(N)cc4OC)cc3F)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.46
HTR4 Q13639 5/20 0.46
ACHE P22303 1/20 0.46
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2C P18825 1/20 0.42
CHRM3 P20309 1/20 0.42
HTR1D P28221 1/20 0.42
ADRA1B P35368 1/20 0.42
HTR2B P41595 1/20 0.42
HTR3A P46098 1/20 0.42
PDE4D Q08499 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
ADRB2 P07550 1/20 0.41
CCR5 P51681 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237656 0.93 HTR4 (0.44) FGFR1HTR4ACHECHRM4CHRM5
SCHEMBL4371223 0.89 HTR4 (0.45) HTR4ACHECHRM3PDE4D
SCHEMBL4233934 0.89 MAPT (0.47) FGFR1HTR4SMN1; SMN2MAPTCCR5
SCHEMBL4236304 0.88 HTR4 (0.49) FGFR1HTR4ACHECHRM4CHRM5
SCHEMBL4228413 0.88 HTR4 (0.49) FGFR1HTR4ACHECHRM4CHRM5
Nitrofen SCHEMBL4234282 0.88 CCR5 (0.40) FGFR1HTR4ACHESMN1; SMN2MAPT
SCHEMBL4242226 0.86 SMN1; SMN2 (0.43) FGFR1PDE4DSMN1; SMN2MAPTGAA
SCHEMBL13699114 0.83 CYP2D6 (0.45) PDE4DSMN1; SMN2MAPTRECQLCYP1A2
SCHEMBL4237553 0.82 WDR5 (0.45) HTR4PDE4DSMN1; SMN2MAPTCCR5
SCHEMBL4236294 0.81 HTR4 (0.45) HTR4CHRM4CHRM5ADRA2CCHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R FGFR1 581/4885HTR4 102/4885ACHE 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.